Form 4: Director Granted Stock Options at LeonaBio

LeonaBio, Inc. reports a Form 4 filing detailing stock option grants to Director Natalie C. Holles.

Summary

• Natalie C. Holles, a Director at LeonaBio, Inc., was granted stock options on June 23, 2026.
• The options have an exercise price of $8.35 and an expiration date of June 22, 2036.
• A total of 2,333 shares are subject to this option grant.
• The shares vest on the earlier of June 23, 2027, or the day before the next annual stockholder meeting after June 22, 2026.
• This grant is part of the Issuer's Outside Director Compensation Policy and is pro-rated based on Holles' appointment date of May 5, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine director compensation event rather than a significant financial or strategic development for the company.

Positives

• Director compensation aligns with company policy, indicating a structured approach to incentivizing board members.
• The grant of stock options suggests management's confidence in future stock performance.
• The pro-rated nature of the grant reflects fair compensation for the partial term of service.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely reports a change in beneficial ownership related to stock options.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology sector, aligning director incentives with shareholder value creation. This type of grant is standard for compensating non-employee directors.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially encouraging long-term value creation. The specific terms of the options will influence their potential future value.

Key Dates

Keywords

Form 4, SEC Filing, Stock Options, Director Compensation, LeonaBio, LONA, Insider Trading, Equity Grant